Press Resease

Pain Management Therapeutics Market - by Drug Class (Anesthetics, NSAIDS, Anticonvulsants, Antidepressants, Anti-migraine agents, Non-narcotic Analgesics, and Opioids (Tramadol, Oxycodone, Hydrocodone, and Others)), by Indication (Neuropathic Pain, Arthritic Pain, Cancer Pain, Post-operative Pain, Chronic Back Pain, Fibromyalgia, and Migraine), and by Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024

Published Date: 20-Sep-2018 Category: Healthcare Report Format : PDF Pages: 130 Report Code: ZMR-3373 Status : Published

The global Pain Management Therapeutics market, which accrued revenue worth nearly USD 61,000 million in 2017 and is slated to garner earnings worth USD 79,500 million by end of 2024, is set to grow at a CAGR of 4% during the period from 2017 to 2024. The report offers valuation and analysis of the Pain Management Therapeutics market on a global as well as regional level.

Description

The global Pain Management Therapeutics market, which accrued revenue worth nearly USD 61,000 million in 2017 and is slated to garner earnings worth USD 79,500 million by end of 2024, is set to grow at a CAGR of 4% during the period from 2017 to 2024. The report offers valuation and analysis of the Pain Management Therapeutics market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. 

Introduction

Apt treatment for pain needs knowing of pain features like the criticality and kind of the pain. For instance, acute pain v/s chronic pain and nociceptive pain v/s neuropathic pain. Additionally, proper treating of pain requires knowledge of the effectiveness of various drugs along with their side-effects. All these aforementioned aspects will steer the expansion of pain management therapeutics industry over the forthcoming years. Reportedly, there are three categories of medicines for treating pain and it includes opioids, acetaminophen, and non-steroidal anti-inflammatory drugs. Apart from this, adjuvant medicines are used for treating neuropathic pain while methadone can control pain more effectively in comparison to many of the opioids.

According to NCBI, pain is considered as the fifth vital biological signal and hence effective managing of the pain has gained massive significance in the recent years. Today, multiple modalities encompassing interventional & non-invasive methods are easily available for treating pain. The treating of acute pain is essential as it can result into chronic one if not treated properly. Furthermore, chronic pain translates into social & psychological problem for both healthcare service provider & patient. Hence, multimodal therapeutics helps the patient manage a large number of pain issues. Apparently, successful pain management therapeutics such as use of opioids for treating chronic nonmalignant pain can prove to benefit both the physician and patient. All these aforementioned aspects are expected to sketch a favorable market growth graph over the forthcoming years.

Market Growth Dynamics

With rise in the number of patients affected due to chronic pain along with easy availability of various kinds of opioid & non-opioid medical treatments, non-pharmacologic therapies, and interventional pain treatments, the pain management therapeutics market is likely to witness accelerated growth within the next couple of years. Apparently, a prominent surge in the aging population prone to chronic pain is likely to translate into humungous expansion of the industry over the forthcoming years. Moreover, a surge in the number of surgeries along with increase in the road accidents & sports injuries are few of the major factors that are anticipated to uplift the market growth over the assessment period.

Furthermore, inflation in the occurrence of chronic ailments including osteoarthritis, cancer, and diabetes will pave a way for geometric progression of the market within the span of next few years. Nevertheless, easy availability of alternative products like pain relief equipment and expiry of patent of prescribed pain killers can decimate the growth of the industry over the years to come.

North American Market Growth To Hit Scalable Heights By 2026

The growth of the market in the region over the forecast timespan is owing to presence of highly structured healthcare sector in the countries like the U.S. and Canada. Apart from this, rapid improvement in the healthcare amenities witnessed in these countries will further contribute towards the regional market size over the forthcoming years. Easy access to proficient & effective treatment alternatives will further embellish the regional market expansion over the forecast timespan. Apparently, increase in the approval of generic medicines by U.S. FDA will steer the business landscape in the sub-continent over the years ahead.  

Key players influencing the market growth and included in the report are Mallinckrodt Pharmaceuticals, Pfizer Inc., Johnson & Johnson Services, Inc., Endo International Plc., GlaxoSmithKline Plc., Novartis AG, Depomed, Inc., Purdue Pharma L.P., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., and Abbott Laboratories. 

This report segments the global pain management therapeutics market as follows:

Global Pain Management Therapeutics Market: Drug Class Segment Analysis

  • Anesthetics
  • NSAIDS
  • Anticonvulsants
  • Antidepressants
  • Anti-migraine agents
  • Non-narcotic analgesics
  • Opioids
    • Tramadol
    • Oxycodone
    • Hydrocodone
    • Others

Global Pain Management Therapeutics Market: Indication Segment Analysis

  • Neuropathic Pain
  • Arthritic Pain
  • Cancer pain
  • Post-operative Pain
  • Chronic Back Pain
  • Fibromyalgia
  • A migraine    

Global Pain Management Therapeutics Market: Distribution Channel Segment Analysis

  • Hospitals Pharmacy 
  • Retail Pharmacy
  • Online Pharmacy 

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Pain Management Therapeutics market, 2017 - 2024(USD Million)
    • 2.2. Global Pain Management Therapeutics market: snapshot
  •  
  • Chapter 3. Pain Management Therapeutics Market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Pain Management Therapeutics market drivers: impact analysis
      • 3.2.2. Favorable Regulatory Scenario
      • 3.2.3. Rising Geriatric Population
      • 3.2.4. Increasing Incidence of Chronic Diseases
    • 3.3. Market Restraints
      • 3.3.1. Global Pain Management Therapeutics market restraints: impact analysis
      • 3.3.2. Availability of Alternative Therapies
      • 3.3.3. Patent Expiration of Prescription Drugs
    • 3.4. Opportunities
      • 3.4.1. Advancements in Drug Development
      • 3.4.2. Untapped Markets in Developing Economies
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Drug Class segment
      • 3.6.2. Market attractiveness analysis, by Indication segment
      • 3.6.3. Market attractiveness analysis, by Distribution Channel segment
      • 3.6.4. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Pain Management Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Pain Management Therapeutics market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Pain Management Therapeutics Market- Drug Class Segment Analysis
    • 5.1. Global Pain Management Therapeutics market: product overview
      • 5.1.1. Global Pain Management Therapeutics market revenue share, by Drug Class, 2017 and 2024
    • 5.2. Anesthetics
      • 5.2.1. Global Pain Management Therapeutics market for Anesthetics, 2017 - 2024(USD Million)
    • 5.3. NSAIDS
      • 5.3.1. Global Pain Management Therapeutics market for NSAIDS, 2017 - 2024 (USD Million)
    • 5.4. Anticonvulsants
      • 5.4.1. Global Pain Management Therapeutics market for Anticonvulsants, 2017 - 2024 (USD Million)
    • 5.5. Antidepressants
      • 5.5.1. Global Pain Management Therapeutics market for Antidepressants, 2017 - 2024 (USD Million)
    • 5.6. Anti-migraine Agents
      • 5.6.1. Global Pain Management Therapeutics market for Anti-migraine Agents, 2017 - 2024 (USD Million)
    • 5.7. Non-narcotic Analgesics
      • 5.7.1. Global Pain Management Therapeutics market for Non-narcotic Analgesics, 2017 - 2024 (USD Million)
    • 5.8. Opioids
      • 5.8.1. Global Pain Management Therapeutics market for Opioids, 2017 - 2024 (USD Million)
        • 5.8.1.1. Tramadol
        • 5.8.1.2. Oxycodone
        • 5.8.1.3. Hydrocodone
        • 5.8.1.4. Others
  •  
  • Chapter 6. Global Pain Management Therapeutics Market- Indication Segment Analysis
    • 6.1. Global Pain Management Therapeutics market: Indication overview
      • 6.1.1. Global Pain Management Therapeutics market revenue share, by Indication, 2017 and 2024
    • 6.2. Neuropathic Pain
      • 6.2.1. Global Pain Management Therapeutics market for Neuropathic Pain, 2017 - 2024 (USD Million)
    • 6.3. Arthritic Pain
      • 6.3.1. Global Pain Management Therapeutics market for Arthritic Pain, 2017 - 2024 (USD Million)
    • 6.4. Cancer Pain
      • 6.4.1. Global Pain Management Therapeutics market for Cancer Pain, 2017 - 2024 (USD Million)
    • 6.5. Post-operative Pain
      • 6.5.1. Global Pain Management Therapeutics market for Post-operative Pain, 2017 - 2024 (USD Million)
    • 6.6. Chronic Back Pain
      • 6.6.1. Global Pain Management Therapeutics market for Chronic Back Pain, 2017 - 2024 (USD Million)
    • 6.7. Fibromyalgia
      • 6.7.1. Global Pain Management Therapeutics market for Fibromyalgia, 2017 - 2024 (USD Million)
    • 6.8. Migraine
      • 6.8.1. Global Pain Management Therapeutics market for Migraine, 2017 - 2024 (USD Million)
  •  
  • Chapter 7. Global Pain Management Therapeutics Market- Distribution Channel Segment Analysis
    • 7.1. Global Pain Management Therapeutics market: Distribution Channel type overview
      • 7.1.1. Global Pain Management Therapeutics market revenue share, by Distribution Channel, 2017 and 2024
    • 7.2. Hospitals Pharmacy
      • 7.2.1. Global Pain Management Therapeutics market for Hospitals Pharmacy, 2017 - 2024 (USD Million)
    • 7.3. Retail Pharmacy
      • 7.3.1. Global Pain Management Therapeutics market for Retail Pharmacy, 2017 - 2024 (USD Million)
    • 7.4. Online Pharmacy
      • 7.4.1. Global Pain Management Therapeutics market for Online Pharmacy,2017 - 2024(USD Million)
  •  
  • Chapter 8. Global Pain Management Therapeutics Market- Regional Segment Analysis
    • 8.1. Global Pain Management Therapeutics market: regional overview
      • 8.1.1. Global Pain Management Therapeutics market revenue share, by region, 2017 and 2024
    • 8.2. North America
      • 8.2.1. North America Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
      • 8.2.2. North America Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
      • 8.2.3. North America Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.2.4. U.S.
        • 8.2.4.1. U.S. Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.2.4.2. U.S. Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.2.4.3. U.S. Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.2.5.2. Rest of North America Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.2.5.3. Rest of North America Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
      • 8.3.2. Europe Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
      • 8.3.3. Europe Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.4. U.K.
        • 8.3.4.1. U.K. Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
        • 8.3.4.2. U.K. Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.4.3. U.K. Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.3.5.2. Germany Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.5.3. Germany Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.3.6.2. France Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.6.3. France Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.7. Italy
        • 8.3.7.1. Italy Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.3.7.2. Italy Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.7.3. Italy Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.8. Spain
        • 8.3.8.1. Spain Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.3.8.2. Spain Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.8.3. Spain Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.3.9. Rest of Europe
        • 8.3.9.1. Rest of Europe Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.3.9.2. Rest of Europe Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.3.9.3. Rest of Europe Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024 (USD Million)
      • 8.4.2. Asia Pacific Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
      • 8.4.3. Asia Pacific Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.4.4.2. China Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.4.4.3. China Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.4.5.2. Japan Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.4.5.3. Japan Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.4.6.2. India Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.4.6.3. India Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.4.7. Southeast Asia
        • 8.4.7.1. Southeast Asia Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.4.7.2. Southeast Asia Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.4.7.3. Southeast Asia Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.4.8.2. Rest of Asia Pacific Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.4.8.3. Rest of Asia Pacific Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.5. Latin America
        • 8.5.1. Latin America Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.5.2. Latin America Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.5.3. Latin America Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.5.4.2. Brazil Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.5.4.3. Brazil Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.5.5.2. Rest of Latin America Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.5.5.3. Rest of Latin America Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
      • 8.6.2. Middle East & Africa Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
      • 8.6.3. Middle East and Africa Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.6.4. GCC Countries
        • 8.6.4.1. GCC Countries Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.6.4.2. GCC Countries Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.6.4.3. GCC Countries Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 8.6.5. Rest of Middle East and Africa
        • 8.6.5.1. Rest of Middle East and Africa Pain Management Therapeutics market revenue, by Drug Class, 2017 - 2024(USD Million)
        • 8.6.5.2. Rest of Middle East & Africa Pain Management Therapeutics market revenue, by Indication, 2017 - 2024(USD Million)
        • 8.6.5.3. Rest of Middle East and Africa Pain Management Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Pfizer Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Endo International plc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Depomed, Inc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Purdue Pharma L.P.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Teva Pharmaceutical Industries Ltd.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Mallinckrodt Pharmaceuticals
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. AstraZeneca plc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Novartis AG
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Merck & Co., Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Johnson & Johnson Services, Inc.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. GlaxoSmithKline plc.
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Product portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Abbott Laboratories
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Product portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments

Methodology

Free Analysis

Pain is a multifarious medical condition, which not only affects the mental but also physical well-being of an individual. The intensity of pain caused due to tissue damage or trauma depends on person to person. The pain is categorized into two main categories, acute and chronic. Depending on the level or condition, the treatment differs. 

The increasing geriatric population, rising prevalence of chronic disease, and favorable regulatory scenario are the key factors contributing towards the growth of pain management therapeutics market globally. The advancement in new drug development for pain management and an untapped market in developing economies are expected to generate immense opportunity for the growth of the market over the forecast period.

Global Pain Management Therapeutics Market

The pain management therapeutics market is categorized into drug class, indication, distribution channel, and by geography. Based on drug class, the pain management therapeutics market is segmented into anesthetics, NSAIDs, anticonvulsants, antidepressants, anti-migraine agents, non-narcotic analgesics, and opioids. The opioids segment is further segmented into tramadol, oxycodone, hydrocodone, and others. By indications, the market for pain management therapeutics market is segmented as neuropathic pain, arthritic pain, post-operative pain, cancer pain, chronic back pain, fibromyalgia, and migraine. Based on the distribution channel, the global pain management therapeutics market is segmented into hospitals pharmacy, retail pharmacy, and online pharmacy. 

By geography, North America is anticipated to register the least growth rate, but in terms of revenue, it dominated the global pain management therapeutics market in 2017. Followed by North America, Europe accounted for the second highest revenue share in the global pain management therapeutics market and is expected to register significant CAGR over the forecast period. The increasing adoption of advanced pain management therapeutics and the ease of availability of sophisticated and well-established healthcare infrastructure are the chief factors contributing towards the high share of Europe and North America in the global pain management therapeutics market.

Some of the key players in the pain management therapeutics market are Pfizer Inc., Endo International Plc., Depomed, Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, AstraZeneca Plc., Novartis AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., and Abbott Laboratories. The growing demand for advanced drug development is increasing the competition among the key players operating in pain management therapeutics market, and this is expected to propel the growth of the pain management therapeutics market globally over the forecast period. 


Frequently Asked Questions

With rise in the number of patients affected due to chronic pain along with easy availability of various kinds of opioid & non-opioid medical treatments, non-pharmacologic therapies, and interventional pain treatments, the pain management therapeutics market is likely to witness accelerated growth within the next couple of years. Apparently, a prominent surge in the aging population prone to chronic pain is likely to translate into humungous expansion of the industry over the forthcoming years. Moreover, a surge in the number of surgeries along with increase in the road accidents & sports injuries are few of the major factors that are anticipated to uplift the market growth over the assessment period.

According to the report, global pain management therapeutics market was valued at approximately USD 61,000 million in 2017 and is expected to generate revenue of around USD 79,500 million by end of 2024, growing at a CAGR of around 4% between 2018 and 2024.

North America is likely to make noteworthy contributions towards overall market revenue. The surge in the expansion of market in the sub-continent over the estimated timespan is credited to presence of highly structured healthcare sector in the countries like the U.S. and Canada. Apart from this, rapid improvement in the healthcare amenities witnessed in these countries will further contribute towards the regional market size over the forthcoming years. Easy access to proficient & effective treatment alternatives will further embellish the regional market expansion over the forecast timespan.

The key players profiled in the report include Mallinckrodt Pharmaceuticals, Pfizer Inc., Johnson & Johnson Services, Inc., Endo International Plc., GlaxoSmithKline Plc., Novartis AG, Depomed, Inc., Purdue Pharma L.P., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., and Abbott Laboratories.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com